The Influence of Levodopa and the COMT Inhibitor on Serum Vitamin B12 and Folate Levels in Parkinson’s Disease Patients

2007 ◽  
Vol 58 (2) ◽  
pp. 96-99 ◽  
Author(s):  
N.I. Triantafyllou ◽  
E. Kararizou ◽  
E. Angelopoulos ◽  
S. Tsounis ◽  
F. Boufidou ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vitamin B12 ◽  
Serum Vitamin ◽  
Comt Inhibitor

Serum vitamin B12 and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion

2010 ◽  
Vol 26 (3) ◽  
pp. 558-559 ◽  
Author(s):  
Diego Santos-García ◽  
Mercedes Macías ◽  
Miguel Llaneza ◽  
Mónica Grande ◽  
Raúl de la Fuente-Fernández
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vitamin B12 ◽  
Serum Vitamin ◽  
Duodenal Levodopa Infusion

Prevalence of Levodopa-Induced Peripheral Neuropathy in Patients with Parkinson’s Disease and Vitamin B12 Deficiency

2021 ◽  
Vol 10 ◽  
pp. 1837
Author(s):  
Mohammad Yazdchi Marandi ◽  
Hormoz Ayromlou ◽  
Safa Najmi ◽  
Seyyed-Reza Sadat-Ebrahimi ◽  
Zakaria Pezeshki ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Peripheral Neuropathy ◽  
Vitamin B12 ◽  
Serum Vitamin ◽  
Vitamin B12 Deficiency ◽  
Term Treatment ◽  
Control Group ◽  
Long Term Treatment ◽  
B12 Deficiency

Background: Parkinson’s disease (PD) is one of the widespread neurodegenerative diseases. Recently, a few studies have suggested that treatment with levodopa and vitamin B12 deficiency may have some role in developing peripheral neuropathy (PN) among PD patients. Hence, the aim of this study was to evaluate PN in patients suffering from PD under long-term treatment with levodopa and also vitamin B12 deficiency in these patients. Materials and Methods: Thirty PD patients who received levodopa for at least two years, 30 levodopa-naïve PD patients, and 30 age-matched controls individuals were included. The participants were subjected to electrodiagnostic tests and the level of vitamin B12 was measured. The prevalence of neuropathy was determined according to electrodiagnostic criteria and compared among the three groups. Results: Overall, 23.3% of cases in levodopa receivers, 3.3% in the levodopa-naïve group, and 3.3% in control group had PN (odds ratio=8.8, 95% confidence interval=1.7-45.6). Levodopa group had significantly lower serum vitamin B12 than the other two groups (P=0.006). Vitamin B12 insufficiency was detected in 36.6% of patients in the levodopa group, which was significantly higher than other groups (23.3% in the levodopa-naïve and 6.6% in the control groups, P=0.02). A significantly negative correlation was noticed between the duration of levodopa exposure and serum level of vitamin B12 (r=-0.31, P=0.016). Conclusion: Our study demonstrated a significantly higher prevalence of vitamin B12 insufficiency and PN in PD patients under treatment with levodopa. Also, our results advocate the role of levodopa in PN development through the vitamin B12 derangement. [GMJ.2021;10:e1837]

scholarly journals Vitamin B12 modulates Parkinson’s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection

Cell Research ◽  
2019 ◽  
Vol 29 (4) ◽  
pp. 313-329 ◽  
Author(s):  
Adam Schaffner ◽  
Xianting Li ◽  
Yacob Gomez-Llorente ◽  
Emmanouela Leandrou ◽  
Anna Memou ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vitamin B12 ◽  
Kinase Activity ◽  
Allosteric Regulation ◽  
Lrrk2 Kinase ◽  
Lrrk2 Kinase Activity

Bone mineral density and serum vitamin D status in Parkinson's disease: Are the stage and clinical features of the disease important?

2020 ◽  
Vol 68 (2) ◽  
pp. 394 ◽  
Author(s):  
ErhanArif Ozturk ◽  
Ibrahim Gundogdu ◽  
Burak Tonuk ◽  
Ebru Umay ◽  
BilgeGonenli Kocer ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Clinical Features ◽  
Bone Mineral ◽  
Serum Vitamin ◽  
Vitamin D Status ◽  
Mineral Density ◽  
Serum Vitamin D

Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia

2020 ◽  
Vol 73 ◽  
pp. 19-22 ◽  
Author(s):  
Stuart J. McCarter ◽  
Cole Stang ◽  
Pierpaolo Turcano ◽  
Michelle M. Mielke ◽  
Farwa Ali ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vitamin B12 ◽  
Lower Risk ◽  
Disease Diagnosis

COMT Inhibitors: Novel Treatments for Parkinson's Disease

CNS Spectrums ◽  
1998 ◽  
Vol 3 (2) ◽  
pp. 53-56 ◽  
Author(s):  
Charles H. Adler
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Comt Inhibitors ◽  
Novel Treatments ◽  
New Class ◽  
Comt Inhibitor ◽  
Duration Of Response

AbstractCatechol-O-methyltransferase (COMT) inhibitors are a new class of medication being developed for the treatment of Parkinson's disease (PD). The enzyme COMT metabolizes levodopa and dopamine, both peripherally and centrally. Coadministration of a COMT inhibitor with levodopa creates an increase in peripheral and central levodopa bioavailability, as well as higher central dopamine concentrations. Because these actions improve the duration of response to levodopa, the COMT inhibitors should prove to be useful adjunctive therapies in PD patients.

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

Synapse ◽  
2002 ◽  
Vol 43 (3) ◽  
pp. 201-207 ◽  
Author(s):  
Roberto Ceravolo ◽  
Paola Piccini ◽  
Dale L. Bailey ◽  
Karin M. Jorga ◽  
Helen Bryson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Comt Inhibitor
Sign in / Sign up

Export Citation Format

Share Document